Comparison of warfarin, rivaroxaban, and dabigatran for effectiveness and safety in atrial fibrillation patients with different CHA2DS2-VASc scores: a retrospective cohort study

MLA

Yue Zhao, et al. “Comparison of Warfarin, Rivaroxaban, and Dabigatran for Effectiveness and Safety in Atrial Fibrillation Patients with Different CHA2DS2-VASc Scores: A Retrospective Cohort Study.” BMC Cardiovascular Disorders, vol. 24, no. 1, July 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12872-024-04020-9.

APA

Yue Zhao, Hong Ren, & Shiwei Xu. (2024). Comparison of warfarin, rivaroxaban, and dabigatran for effectiveness and safety in atrial fibrillation patients with different CHA2DS2-VASc scores: a retrospective cohort study. BMC Cardiovascular Disorders, 24(1), 1–11. https://doi.org/10.1186/s12872-024-04020-9

Chicago

Yue Zhao, Hong Ren, and Shiwei Xu. 2024. “Comparison of Warfarin, Rivaroxaban, and Dabigatran for Effectiveness and Safety in Atrial Fibrillation Patients with Different CHA2DS2-VASc Scores: A Retrospective Cohort Study.” BMC Cardiovascular Disorders 24 (1): 1–11. doi:10.1186/s12872-024-04020-9.